Spotlight on mavrilimumab for the treatment of rheumatoid arthritis: evidence to date

Overview of attention for article published in Drug Design, Development and Therapy, January 2017

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (74th percentile)
Good Attention Score compared to outputs of the same age and source (73rd percentile)

So far, Altmetric has seen 5 X posts from 5 X users, with an upper bound of 10,714 followers.

RT @fezziwig2019: $KNSA Mavrilimumab targets the subunit α of GM-CSF receptor (Ra) https://t.co/qjdIq4n8yy which is less well expressed by…

RT @RheumNow: Clinical review of anti-GMCSF mAb-mavrilimumab. Preclinical, Phase I/II efficacy & safety in #RA; 60-70% ACR20 resp https://t…

A proud Melbourne innovation, from hard work in basic science #unimelb #wehi https://t.co/zyicxOkH2Z

Clinical review of anti-GMCSF mAb-mavrilimumab. Preclinical, Phase I/II efficacy & safety in #RA; 60-70% ACR20 resp https://t.co/7dnJzqOZeX